Pharmaceutical compounds and uses thereof
AssigneeRegents of the University of Minnesota
InventorsDaQing Yang, Carston R. Wagner, Aniekan Okon
Life of this patent
Estimating the term…
Abstract
Described herein are small molecule cap-dependent inhibitors, including the compound of the formula: which compounds that can induce the accumulation of the p53 tumor suppressor protein in cancer cells that still express wild-type p53, as well as methods of using those compounds to, among other things, treat neuroblastoma, pediatric glioblastoma multiforme or breast cancer.
Claims7
A compound of the formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- X− represents a counterion;
- R1 and R2 are each independently H, OH or alkoxy;
- R3 is alkyl, aryl or heterocyclyl;
- R4 is alkyl or aryl;
- R5 is aryl;
- and
- X1 is NH, S or O;
- wherein the heterocyclyl is selected from the group consisting of piperidinyl, piperazinyl, morpholinyl, furanyl, pyrrolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, triazinyl, thiophenyl, tetrahydrofuranyl, pyrrolyl, oxazolyl, imidazolyl, triazolyl, tetrazolyl, indolyl, benzoxazolinyl, and benzimidazolinyl groups.
A method for treating neuroblastoma, pediatric glioblastoma multiforme or breast cancer comprising administering a therapeutically effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof, wherein X− represents a counterion, to a subject in need thereof.
A compound having the formula:
- or a pharmaceutically acceptable salt thereof, wherein X− represents a counterion.
Dependencies are inferred from the claim text.